Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line

Chronic myelogenous leukemia (CML) is associated with the high TK activity chimeric protein BCR